One Infusion. A Permanent Gene Edit. Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.

MAY 28, 2026 • PAID

Thoughts on Healthcare Markets & Technology is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Video Preview



🎧 Part I Podcast free on Spotify.

Thoughts on Healthcare Markets & Technology

🎧 **Part I: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.**

VERVE-102 just published Phase 1b data in NEJM. Single IV infusion. 88% PCSK9 reduction. 62% LDL-C reduction. 18-month durability. No serious adverse events in 35 patients...

▶ Listen now

10 hours ago · Thoughts on Healthcare

🎧 Part II Podcast episode for paid subscribers only. Also available on Spotify.

Thoughts on Healthcare Markets & Technology

🎧 **Part II: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.**

VERVE-102 just published Phase 1b data in NEJM. Single IV infusion. 88% PCSK9 reduction. 62% LDL-C reduction. 18-month durability. No serious adverse events in 35 patients...

Listen now

10 hours ago · Thoughts on Healthcare

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the s settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

The New England Journal of Medicine published the Heart-2 Phase 1b data for VERVE-102 last week. Single IV infusion. Adenine base editor targeting PCSK9 hepatocytes. Delivered via a GalNAc-decorated lipid nanoparticle. 35 participan across six dose cohorts. The top-line numbers: up to 88% PCSK9 reduction, up t LDL-C reduction, durability holding out to 18 months. No treatment-related se adverse events. All 35 participants received their full planned dose. FDA Fast Tr designation in hand. Lilly has already exercised its opt-in right under the collaboration agreement.

The question worth asking is not whether those numbers are good – they clearly but what they actually mean at the level of biology, business model, and competi positioning in a therapeutic category that already has multiple approved and eff options. The answer is more interesting than the headline.

Key points:

- VERVE-102 is not trying to beat statins or PCSK9 inhibitors on efficacy. It i trying to beat chronic therapy on permanence.
- The GalNAc-LNP delivery choice is the critical technical difference from VI 101, and so far the safety profile is holding.
- The dose-response curve has a non-obvious shape that matters for understa where this program is actually operating.
- Lilly's opt-in structure (33% dev costs, 50/50 US commercialization) is a real about institutional conviction, not just option value maintenance.

- The business model question for a one-time gene therapy in a large, chronic population is genuinely unresolved and more complex than rare disease pric precedents suggest.
- What still has to happen between here and approval is substantial, and the 1 year follow-up study is the dataset that ultimately settles the durability argu

Table of Contents

1. The Problem VERVE-102 Is Actually Solving
2. What the Heart-2 Data Says and What It Doesn't
3. The Mechanism Worth Understanding
4. Why Durability Is the Only Number That Matters
5. The Business Model Inversion
6. What Lilly's Opt-In Actually Signals
7. The Platform Behind the Program
8. What Still Has to Happen

The Problem VERVE-102 Is Actually Solving

There is a thing that happens in cardiovascular medicine that almost nobody tal about in polite company. The drugs work. Statins produce meaningful, reproduc LDL reductions. PCSK9 inhibitors – evolocumab, alirocumab – work even bette delivering 50-60% LDL-C reductions with years of cardiovascular outcomes data behind them. Inclisiran, Novartis's RNA interference approach, gets you to simil reductions with twice-yearly dosing. The JUPITER trial, the FOURIER trial, the ODYSSEY OUTCOMES trial – the evidence base for aggressive LDL lowering in high-risk populations is about as clean as you get in clinical pharmacology. The science of LDL control is not the problem.

The problem is that approximately half of patients who are prescribed lipid-low therapy discontinue it within a year.

That number has been consistent across studies, across geographies, and across classes for a long time. It shows up in claims data, in pharmacy fill records, in pc market surveillance. It is not a rounding error or a single bad dataset. It is a stru feature of how humans interact with chronic disease management when they fee most of the time, the downstream cardiovascular risk is abstract, and the daily o biweekly or monthly intervention requires effort to maintain. The drugs are wor The patients are stopping.

This is the actual clinical problem Verve Therapeutics was founded to solve. No out-efficacy the PCSK9 inhibitors that already exist. Not to find a better mechan than statins for LDL receptor regulation. To make the treatment permanent so t adherence becomes irrelevant. One infusion, once in a patient's life, and the PCS gene in their liver is edited at the nucleotide level. The LDL receptors recycle. L stays down. No refill required. No injection schedule. No copay reminders. The problem the company is attacking is not biology – it is human behavior in the co of chronic disease, and they are trying to solve it by eliminating the chronic part

That is the framing that makes the NEJM data interesting to investors and entrepreneurs. Not the specific numbers on PCSK9 reduction at the 1.0 mg/kg c The question is whether base editing is a real enough, durable enough, safe enou mechanism to permanently remove the adherence problem from the LDL loweri equation. The Heart-2 data is an early and incomplete answer to that question, b is the first human data that makes it look like a real answer rather than a hypoth

What the Heart-2 Data Says and What Doesn't

← Previous